AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

Additionally, positive findings from trials like ADRIATIC (NCT03703297) and IMforte (NCT05091567) are further shaping ...

The new indication adds to Imfinzi's FDA-approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which have helped drive sales of the PD-L1 inhibitor to $1.3 ...

Its product lineup is anchored by its oncology offerings, with drugs including Enhertu, Tagrisso, and Imfinzi as key ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.

One option is an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy medicines work by helping your immune system find and attack cancer cells. The FDA approved Imfinzi in 2017.

The pharma giant confirmed that Wang Lei, the executive vice president who oversaw AstraZeneca’s rapid expansion in China, is ...

Now, a newer option is available: an immunotherapy medicine called Imfinzi (durvalumab). Immunotherapy medicines work by helping your immune system find and attack cancer cells. The FDA approved ...

Arcus Biosciences has a promising pipeline with five Phase 3 trials focused on GI and NSCLC cancers. Learn why RCUS stock ...

Other key accomplishments and milestones in 2024 include: Metastatic Pancreatic Ductal Adenocarcinoma Commenced enrollment ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...